Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: C242-DM1, ImmunoGen Inc.

¹Suzanne_Smith162@hotmail.com

Current Opinion in Molecular Therapeutics

|May 8, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incidental finding of endolymphatic stromal myosis during luteinizing hormone releasing hormone agonist therapy for suspected benign uterine myomata. A case report.

The Journal of reproductive medicine·1992

Same author

Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide.

Archives of surgery (Chicago, Ill. : 1960)·1992

Same author

Respiratory epithelial cell invasion by group B streptococci.

Infection and immunity·1992

Same author

Psychiatrists and their patients--confidential information in the wake of spycatcher.

The Australian and New Zealand journal of psychiatry·1992

Same author

Continuous catheter drainage of Streptococcus pneumoniae pericardial effusion.

Journal of the Royal Society of Medicine·1992

Same author

Index of suspicion. Case 1. Diagnosis: Klinefelter syndrome.

Pediatrics in review·1992

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

C242-DM1, an immunotoxin targeting colon cancer, demonstrated complete tumor regression in preclinical models. Studies in monkeys showed no significant toxicity, supporting its potential as a cancer therapeutic.

Area of Science:

Oncology
Immunotherapy
Drug Development

Background:

C242-DM1 is an investigational immunotoxin developed for colon cancer treatment.
It comprises a colon cancer-targeting antibody (C242) linked to a maytansine derivative (DM1).

Purpose of the Study:

To evaluate the efficacy and safety of C242-DM1 in preclinical cancer models.
To assess the potential of C242-DM1 as a therapeutic agent for various cancers.

Main Methods:

Preclinical studies in animal models of pancreatic, non-small cell lung, and colon cancer.
Evaluation of an immunoconjugate combination (J591-DM1) for prostate cancer cells.
Toxicology studies in non-human primates.

Main Results:

Related Experiment Videos

C242-DM1 achieved complete tumor regression in animal models at non-toxic doses.
J591-DM1 showed effective, antigen-specific drug delivery to prostate cancer cells with low systemic toxicity.
Monkey studies indicated no significant toxicity or side effects at doses exceeding those effective in mice.

Conclusions:

C242-DM1 exhibits potent anti-tumor activity and a favorable safety profile in preclinical settings.
The immunotoxin holds promise for the treatment of colon cancer and potentially other malignancies.
Further clinical development is warranted based on these promising preclinical findings.